Abstract Details

Title The Relationship between Vitamin D and Cognitive Performance in Persons with Parkinson's

Topic Movement Disorders

Presentation(s) P04 - (-)

Poster/Presentation
Number 170

Objective

Background BACKGROUND: The discovery of vitamin D receptors throughout the brain and the role of vitamin D in neurodevelopment have led researchers to examine this fat soluble vitamin in relation to cognition. Observational studies of vitamin D and cognitive function or decline are inconsistent. To our knowledge, the association between vitamin D status and cognitive function in a large population with Parkinson's disease has not been reported.

Design/Methods DESIGN/METHODS: This is an add-on study to a longitudinal study following memory function in persons with Parkinson's disease. Baseline cognitive tests and serum 25-hydroxyvitamin D measured by radioimmunoassay were examined for 298 participants with Parkinson's disease. Measures of global function (MMSE, MOCA, Mattis Dementia Scale), verbal memory (Hopkins Verbal Learning Test), and fluency (animals and vegetables) were administered. Linear regression assessed the association between vitamin D and cognitive function. Correlations were examined between each cognitive test and vitamin D concentrations in the entire cohort (n=298) as well in the non-demented subset of the cohort (n=233). All comparisons were corrected for age, disease duration, and Hoehn&Yahr score.

Results RESULTS: Significant correlations were found between vitamin D concentrations and fluency for naming vegetables (p=0.01) when looking at all participants. In the non-demented sub-set, vitamin D concentration was positively correlated with verbal fluency (animal fluency (p=0.05), vegetable fluency (p<0.01)), and memory (Hopkins Verbal Learning Test (total recall on immediate recall p=0.02 and true positives on delayed recall (p=0.04)).

Conclusions CONCLUSIONS: The association between vitamin D and better cognitive function in Parkinson's subjects free of dementia suggests that future vitamin D interventions to slow cognitive decline in Parkinson's should be employed prior to the incidence of cognitive impairment.

Authors/Disclosures
Amie L. Hiller, MD PRESENTER	The institution of Dr. Hiller has received research support from Admas Pharmaceuticals.
	No disclosure on file
Cyrus P. Zabetian, MD (VA Puget Sound Health Care System)	The institution of Dr. Zabetian has received research support from American Parkinson Disease Association. The institution of Dr. Zabetian has received research support from Department of Veterans Affairs. The institution of Dr. Zabetian has received research support from NIH. Dr. Zabetian has a non-compensated relationship as a Member, Scientific Advisory Council with Lewy Body Dementia Association that is relevant to AAN interests or activities.
James B. Leverenz, MD, FAAN (Cleveland Clinic)	Dr. Leverenz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acadia. Dr. Leverenz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Leverenz has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eisai.
	No disclosure on file
Thomas J. Montine, MD, PhD	Dr. Montine has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Enable Medicine. Dr. Montine has stock in Enable Medicine. The institution of Dr. Montine has received research support from NIH. The institution of Dr. Montine has received research support from MJFF. Dr. Montine has received intellectual property interests from a discovery or technology relating to health care. Dr. Montine has received publishing royalties from a publication relating to health care.
	No disclosure on file
Gene L. Bowman, ND (Harvard Medical School, Massachusetts General Brigham)	No disclosure on file
Matthew L. Flaherty, MD	Dr. Flaherty has received personal compensation for serving as an employee of Sense Diagnostics, Inc. Dr. Flaherty has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Boeringher Engelheim. Dr. Flaherty has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for CSL Behring. Dr. Flaherty has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Alexion. Dr. Flaherty has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for various law firms. Dr. Flaherty has stock in Sense Diagnostics, Inc. The institution of Dr. Flaherty has received research support from NINDS. Dr. Flaherty has received intellectual property interests from a discovery or technology relating to health care.
Joseph F. Quinn, MD, FAAN (OHSU Neurology)	Dr. Quinn has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Retrophin. Dr. Quinn has received personal compensation in the range of $500-$4,999 for serving as a DSMB with Alzheimer's Disease Cooperative Study. Dr. Quinn has received personal compensation in the range of $500-$4,999 for serving as a DSMB with Alzheimer's Therapeutic Research Institute. Dr. Quinn has a non-compensated relationship as a consultant with Cognition Therapeutics that is relevant to AAN interests or activities.

��ɫ��

��ɫ��